Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Entain reports strong Q1 trading, appoints Stella David as permanent boss

(Sharecast News) - Entain has officially appointed interim boss Stella David as its new chief executive, as the sports betting and gaming group reported a strong start to the year with net gaming revenues ahead of expectations. David, Entain's chair who stepped in as acting CEO in February after the departure of Gavin Isaacs, will be made permanent CEO effective immediately, the company announced on Tuesday.

"Stella has played a pivotal role in shaping, implementing and executing the ongoing delivery of Entain's strategy to drive value for our shareholders," said interim chair Pierre Bouchut.

"She is highly regarded by our stakeholders, and her appointment provides consistency and stability as the business pursues its many growth opportunities."

The news came as Entain reported a better-than-expected performance over the three months to 31 March, with net gaming revenue (NGR) up 11% over the year before at constant currency, with strong performances online at Entain's core brands and its 50% share in US business BetMGM.

At BetMGM, NGR surged 34% at constant currencies, driving by the iGaming business, as well a "strengthened sports product and refined player engagement", Entain said.

"Entain reiterates its expectation for Online NGR growth of mid-single-digit percent in 2025 on a constant currency basis and remains comfortable with market expectations for FY2025 EBITDA," the company said. Company-compiled consensus forecasts for 2025 EBITDA currently stand at £1.11bn, up from £1.09bn in 2024.

Entain's share price was up 3.2% at 648.2p in early deals.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.